Abstract
Background: Quantitation of serum hepatitis B virus (HBV) DNA has proven useful in assisting with patient management and treatment and several commercially available assays have been developed to quantify serum HBV‐DNA levels. Methods: The performance of the cross‐linking assay and the branched‐DNA signal amplification (bDNA) assay for the quantitative measurement of HBV‐DNA was studied in 99 hepatitis B surface antigen‐positive and viraemic patients. Results: Of these samples, 82 (83%) were positive for HBV‐DNA by both assays and four (4%) were below the cut‐off for both assays. Of the remaining 13 samples, 10 contained measurable levels of HBV‐DNA by the cross‐linking assay alone and three other samples contained measurable levels of HBV‐DNA by the bDNA assay alone. The sensitivity gain of the cross‐linking assay relative to bDNA assay in this study population was 10/92 (11%). In addition, a linear regression analysis showed that the HBV‐DNA levels obtained from both assays was significantly correlated (γ = 0.974, P < 0.0001). Conclusions: These findings suggest that the recently developed cross‐linking assay is more sensitive than the bDNA assay for the quantitative determination of HBV‐DNA.

This publication has 11 references indexed in Scilit: